natgillin/translations-raw huggingface dataset:
wherein the fraction of viable cells in the cell population can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total conditioned medium present in the portion of the cell culture conditioned medium not containing cells of the cell population. 
pri čemu se udio vijabilnih stanica u populaciji stanica može izračunati prema formuli: [image] pri čemu [image] i f je udio ukupnog kondicioniranog medija koji se nalazi u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica.
The method of claim 1, wherein the method is a method of measuring the fraction of viable cells in a tissue-engineered product maintained in a cell culture medium, and wherein the method comprises: 
Postupak prema zahtjevu 1, naznačen time da postupak je postupak mjerenja udjela vijabilnih stanica u produktu preinačenog-tkiva održavanom u mediju za kulturu stanica, te pri čemu se postupak sastoji od:
disrupting the membrane integrity of the cells in a portion of the cell culture medium containing cells of the tissue-engineered product; 
narušavanja integriteta membrane stanica u dijelu medija stanične kulture koji sadrži stanice produkta preinačenog-tkiva;
comparing the level of cell death-stable enzyme activity (X) in the portion of the cell culture medium containing cells and conditioned medium of the tissue-engineered product to the level of cell death-stable enzyme activity (Y) in the portion of the cell culture conditioned medium not containing cells of the tissue-engineered product, wherein the fraction of viable cells in the tissue-engineered product can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total conditioned medium present in the portion of the cell culture conditioned medium not containing cells of the cell population. 
usporedbe razine enzimske aktivnosti stabilne stanične smrti (X) u dijelu medija stanične kulture koji sadrži stanice i kondicionirani medij produkta preinačenog-tkiva prema razini enzimske aktivnosti stabilne stanične smrti (Y) u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice produkta preinačenog-tkiva, pri čemu udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli: [image] pri čemu [image] i f je udio ukupnog kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica.
The method of claim 1, wherein the method is a method of measuring the fraction of viable cells in a tissue-engineered product maintained in a cell culture medium, and wherein the method comprises: 
Postupak prema zahtjevu 1, naznačen time da postupak je postupak mjerenja udjela vijabilnih stanica u produktu preinačenog-tkiva održavanoj u mediju za kulturu stanica, te pri čemu se postupak sastoji od:
providing a sample portion of the tissue-engineered product containing cells and a proportional amount of a cell culture conditioned medium; 
pripreme dijela uzorka produkta preinačenog-tkiva koji sadržava stanice i proporcionalnu količinu kondicioniranog medija stanične kulture;
comparing the level of cell death-stable enzyme activity detected in steps (b) and (d), wherein when the ratio of the percentage of total cells to the percentage of total cell culture conditioned medium in the sample portion is 1:1, the fraction of viable cells in the tissue-engineered product can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total sample conditioned medium present in the portion of the cell culture conditioned medium not containing cells of the cell population; 
usporedbe razine enzimske aktivnosti stabilne stanične smrti određene u koracima (b) i (d), pri čemu kada je omjer ukupnog postotka stanica prema ukupnom postotku kondicioniranog medija stanične kulture u dijelu uzorka 1:1, udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli: [image] pri čemu [image] i f je udio ukupnog uzorka kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica;
and wherein when the ratio of the percentage of cells to the percentage of cell culture conditioned medium in the sample portion deviates from 1:1, the fraction of viable cells in the tissue-engineered product can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total sample conditioned medium present in portion of the cell culture conditioned medium not containing cells of the cell population; 
i pri čemu kada je omjer postotka stanica prema postotku kondicioniranog medija stanične kulture u dijelu uzorka odstupa od 1:1, udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli: [image] pri čemu [image] i f je udio ukupnog uzorka kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadrži stanice iz populacije stanica;
The method of claim 3, wherein the membrane integrity of the cells in the sample portion of the tissue-engineered product is disrupted by shearing, sonication, low barometric pressure, high temperature, low temperature, chemical or enzymatic lysis, or membrane decoupling agents. 
Postupak prema zahtjevu 3, naznačen time da se membranski integritet stanica u dijelu uzorka produkta preinačenog-tkiva poremećuje smicanjem, sonikacijom, niskim barometarskim tlakom, visokom temperaturom, niskom temperaturom, kemijskom ili enzimskom lizom, ili agensima za membransko razdvajanje.
The method of claim 4, wherein the membrane integrity of the cells in the sample portion of the tissue-engineered product is disrupted by the addition of an amphiphile. 
Postupak prema zahtjevu 4, naznačen time da se membranski integritet stanica u dijelu uzorka produkta preinačenog-tkiva poremećuje dodavanjem amfifila.
providing a portion of the tissue-engineered product containing cells and a proportional amount of the cell culture conditioned medium; 
pripreme dijela produkta preinačenog-tkiva koji sadržava stanice i proporcionalnu količinu kondicioniranog medija stanične kulture;
providing a portion of the cell culture conditioned medium, provided in step a), not containing cells of the tissue-engineered product; 
pripreme dijela kondicioniranog medija stanične kulture, pripremljenog u koraku a), koji ne sadržava stanice produkta preinačenog-tkiva;
A method of measuring the cytotoxicity of a treatment to cells in a tissue-engineered product maintained in a cell culture medium comprising: 
Postupak mjerenja citotoksičnosti tretmana sa stanicama u produktu preinačenog-tkiva održavanoj u mediju za kulturu stanica naznačen time da se sastoji od:
applying the treatment to the tissue-engineered product; 
primjene tretmana na produkt preinačenog-tkiva;
detection of the leaving group, wherein the amount of leaving group detected is proportional to the level of cell death-stable enzyme activity. 
otkrivanja odlazne skupine, pri čemu je količina otkrivenih odlaznih skupina proporcionalna sa razinom enzimske aktivnosti stabilne stanične smrti.
The method of claim 16, further comprising the step of adding an agent which modulates the signal of the detectable leaving group. 
Postupak prema zahtjevu 16, naznačen time da dodatno sadrži korak dodavanja agensa koji modulira signal odlazne skupine koju se može otkriti.
The method of claim 24, wherein the agent which modulates the signal of the leaving group, attenuates the signal of the leaving group. 
Postupak prema zahtjevu 24, naznačen time da agens koji modulira signal odlazne skupine, slabi signal odlazne skupine.
The dairy product according to claim 10 or 11, wherein said dairy product is a fermented milk, a yogurt, a matured cream, a cheese, a fromage frais, a milk drink, a dairy product retentate, a processed cheese, a cream dessert, a cottage cheese or an infant milk. 
Mliječni proizvod prema zahtjevu 10 ili 11, gdje je taj mliječni proizvod fermentirano mlijeko, jogurt, zrelo vrhnje, sir, svježi sirevi, mliječni napitak, koncentrat (retentat) mliječnog proizvoda, obrađeni sir, kremasti desert, zrnati sir ili dječje mlijeko.
further providing a silylated base of formula (II): wherein R2 is a protecting group, preferably a trimethylsilyl (TMS)-residue; 
te se dodatno osigurava sililirana baza sa formulom (II): [image] pri čemu R2 je zaštitna skupina, poželjno trimetilsilil (TMS)-ostatak;
reacting the compound of formula (I) and the compound of formula (II) together in a suitable anhydrous solvent and in the presence of a suitable catalyst, whereby the compound of formula (III) is obtained, characterized in that said catalyst is a salt of an aliphatic sulphonic acid or a salt of a fluorinated aliphatic sulphonic acid. 
međusobnom reakcijom spoja s formulom (I) i spoja s formulom (II) u pogodnom bezvodnom otapalu i u prisutnosti prikladnog katalizatora, pri čemu se dobiva spoj s formulom (III), naznačen time da navedeni katalizator je sol alifatske sulfonske kiseline ili sol fluorirane alifatske sulfonske kiseline.
Method according to claim 1 or 2, characterized in that the catalyst used in said reaction is a salt of methylsulphonic acid or of ethylsulphonic acid, or a salt of trifluoromethane-sulfonic acid, pentafluoroethyl-sulfonic acid, or heptafluoropropyl-sulfonic acid. 
Postupak prema zahtjevu 1 ili 2, naznačen time da katalizator koji se koristi u navedenoj reakciji je sol metilsulfonske kiseline ili etilsulfonske kiseline, ili sol trifluorometan-sulfonske kiseline, pentafluoroetil-sulfonske kiseline, ili heptafluoropropil-sulfonske kiseline.
Method according to claim 3, characterized in that the catalyst is a salt of methylsulphonic acid and/or the salts of trifluoromethanesulfonic acid. 
Postupak prema zahtjevu 3, naznačen time da je katalizator sol metilsulfonske kiseline i/ili soli trifluorometansulfonske kiseline.
Method according to claim 1-4, characterized in that the catalyst is chosen from the salts comprising salts of scandium, preferably Sc(OTf)3, of zinc preferably Zn(OTf)2, or of copper preferably Cu(OTf)2. 
Postupak prema zahtjevu 1-4, naznačen time da je katalizator odabran od soli koje sadrže soli skandija, poželjno Sc(OTf)3, cinka poželjno Zn(OTf)2, ili bakra poželjno Cu(OTf)2.
m is zero, one, two or three; 
m je nula, jedan, dva ili tri;
n is zero, one, two or three; 
n je nula, jedan, dva ili tri;
p is zero, one, two or three; 
p je nula, jedan, dva ili tri;
or two R4 groups on the same carbon atom may be taken together to form an oxo (=O) radical or a (C3-C6)spirocycloalkyl; 
ili se dvije skupine R4 na istom atomu ugljika može uzeti zajedno kako bi tvorile okso (=O) radikal ili (C3-C6)spirocikloalkil;
The aqueous formulation of any one of the claims 1 to 3 comprising an analogue of exendin-4 selected from a group comprising lixisenatide, exenatide and liraglutide. 
Vodena formulacija u skladu s patentnim zahtjevom 1, naznačena time što sadrži analog eksendina-4, kojeg se bira iz skupine koju čine liksisenatid, eksenatid i liraglutid.
Process according to claim 1, wherein step ii) consists in evaluating antibodies by BRET analysis on cells expressing both CXCR4-RLuc/CXCR4-YFP and selecting antibodies capable to inhibit at least 40 %, of the BRET signal. 
Postupak prema patentnom zahtjevu 1, naznačen time da korak ii) obuhvaća evaluaciju antitijela BRET analizom stanica koje eksprimiraju oba CXCR4-RLuc/CXCR4-YFP i odabir antitijela koji mogu inhibirati najmanje 40% signala BRET.
Process according to claim 1, wherein step iii) consists in evaluating antibodies by BRET analysis on cells expressing both CXCR4-RLuc/CXCR2-YFP and selecting antibodies capable to inhibit at least 40 %, of the BRET signal. 
Postupak prema patentnom zahtjevu 1, naznačen time da korak iii) obuhvaća evaluaciju antitijela BRET analizom stanica koje eksprimiraju oba CXCR4-RLuc/CXCR4-YFP i odabir antitijela koji mogu inhibirati najmanje 40% signala BRET.
A vector composed of a nucleic acid according to claim 9. 
Vektor, naznačen time da je sastavljen od nukleinske kiseline prema patentnom zahtjevu 9.
A composition according to claim 22, characterized in that it comprises, in addition, as a combination product for use in a simultaneous, separated or extended fashion, an anti-tumor antibody other that an antibody directed against CXCR4. 
Farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time da dodatno kao kombinacijski ili konjugirani produkt za istodobnu, odvojenu ili produljenu upotrebu sadrži antitumorsko antitijelo koje nije antitijelo usmjereno na CXCR4.
Use of the compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in claim 7 for the production of pharmaceutical compositions for the treatment of atopic eczema. 
Uporaba spoja formule I ili njegove soli, njegovog N-oksida ili soli od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
An inhaler for delivering dry-powder medicament to a patient from an open blister pocket of a blister pack (1), the blister pack (1) having a plurality of blister pockets (3) spaced apart in a length direction of the pack (1) and each containing a measured dose of the medicament, the inhaler comprising: 
Inhalator za dostavu lijeka u obliku suhog praha pacijentu iz otvorenog džepa blistera iz pakiranja blistera (1), pakiranje blistera (1) ima množinu džepova blistera (3) odvojenih u dužnom smjeru pakiranja (1) i svaki sadrži izmjerenu dozu lijeka, inhalator obuhvaća:
An inhaler according to claim 1, wherein the manifold is arranged such that, in use, air is drawn into the manifold solely through the air inlet (125). 
Inhalator u skladu s patentnim zahtjevom 1, pri čemu je cjevovod postavljen tako da je, u uporabi, zrak uvučen u cjevovod jedino kroz ulaz zraka (125).
An inhaler according to claim 1 or 2, wherein the air inlet (125) of the manifold defines the sole point for entry for external air into the inhaler. 
Inhalator u skladu s patentnim zahtjevom 1 ili 2, pri čemu ulaz zraka (125) cjevovoda određuje jedinu točku za ulaz za vanjski zrak u inhalator.
An inhaler according to any preceding claim, wherein the air inlet (125) of the manifold has art elongate cross-sectional shape, and wherein the cross-sectional area of the manifold reduces in the airflow direction. 
Inhalator u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu ulaz zraka (125) cjevovoda ima izraženo izduženi oblik poprečnog presjeka, i pri čemu se površina poprečnog presjeka cjevovoda smanjuje u smjeru protoka zraka.
An inhaler according to any preceding claim, wherein the unitary component further defines a mouthpiece (133) arranged to receive, in use, the entrained medicament from the air outlet (129) of the manifold. 
Inhalator u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu jedinstvena sastavnica nadalje određuje dio za usta (133) postavljen da prihvaća, u uporabi, uneseni lijek iz izlaza zraka (129) cjevovoda.
An inhaler according to claim 8 or 9, wherein the cross-sectional area of the mouthpiece (133) increases in the airflow direction. 
Inhalator u skladu s patentnim zahtjevom 8 ili 9, pri čemu se područje poprečnog presjeka dijela za usta (133) povećava u smjeru protoka zraka.
Method of detecting Pneumocandin B0 and/or Pneumocandin C0 in a sample, wherein Pneumocandin B0 specific fragment and/or Pneumocandin C0 specific fragment is/are detected using tandem Mass Spectrometry in negative mode. 
Postupak za detekciju Pneumokandina B0 i/ili Pneumokandina C0 u uzorku, naznačen time da se specifični fragment Pneumokandina B0 i/ili specifični fragment Pneumokandina C0 detektira korištenjem tandem masene spektrometrije u negativnom načinu rada.
The method of claim 9, wherein the collision energy is approximately 60 V. 
Postupak prema zahtjevu 9, naznačen time da je energija sudara približno 60 V.
The method of claim 1, wherein the specific fragment for Pneumocandin C0 is approximately m / z 507 at a collision energy of approximately 45-60 V. 
Postupak prema zahtjevu 1, naznačen time da je specifični fragment za Pneumokandin C0 približno m/z 507 kod energije sudara od približno 45-60 V.
A compound according to claim 11, wherein R2 is isopropoxy, or a salt of such a compound. 
Spoj prema zahtjevu 11, naznačen time, da R2 je izopropoksi, ili sol toga spoja.
or salts of these compounds. A compound according to claim 1, selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier material. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 19, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivu tvar kao nosač.
The composition of claim 1 wherein the KGF is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što je KGF izabran iz grupe koju čine SEQ ID NO: 2, SEQ ID NO: 3.
A method for making a lyophilized KGF composition according to claim 1 comprising the steps of 
Postupak za pripremu liofilizirane KGF kompozicije prema patentnom zahtjevu 1 koji sadrži korake
lyophilizing said KGF solution to obtain said lyophilized KGF composition. 
liofilizacije navedene otopine KGF da bi se dobila navedena liofilizirana kompozicija KGF.
The method of claim 12 wherein the KGF is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3. 
Postupak prema patentnom zahtjevu 12 naznačen time što je KGF izabran iz grupe koju čine SEQ ID NO: 2, SEQ ID NO: 3.
A compound of formula (I): wherein: 
Spoj čija je formula (I):
A compound of formula (I) as claimed in claims 1 to 5 wherein R6 is hydroxy or C1-6 alkyl optionally substituted by piperidinyl, piperazinyl, morpholinyl, homomorpholinyl or homopiperazinyl. 
Spoj formule (I) prema zahtjevima 1 do 3, naznačen time da je R6 hidroksi ili C1-6 alkil opcionalno supstituiran piperidinilom, piperazinilom, morfolinilom, homomorfolinilom ili homopiperazinilom.
A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof as claimed in claims 1 to 6, and a pharmaceutically acceptable adjuvant, diluent or carrier. 
Farmaceutski pripravak koji sadrži spoj formule (I), ili neka njegova farmaceutski prihvatljiva sol prema zahtjevima 1 do 4, te neki farmaceutski prihvatljivi adjuvant, razrjeđivač ili nosač.
The use of a salt of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine selected from the DL-lactic acid addition salt, L-lactic acid addition salt and the D-lactic acid addition salt in the manufacture of a liquid formulation for the treatment of a disease selected from mood disorders; major depressive disorder; general anxiety disorder; panic disorder; post traumatic stress disorder; depression associated with cognitive impairment, Alzheimer's disease or anxiety; depression with residual symptoms; chronic pain; eating disorder or abuse, wherein said salt is in a liquid formulation. 
Uporaba soli 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina izabrane između dodatka soli DL-mliječne kiseline, dodatka soli L-mliječne kiseline i dodatka soli D-mliječne kiseline u proizvodnji tekuće formulacije za liječenje bolesti odabrane između poremećaja raspoloženja; značajnog depresivnog poremećaja; općeg anksioznog poremećaja; paničnog poremećaja; posttraumatskog stresnog poremećaja; depresije povezane s kognitivnim nedostatkom, Alzheimerove bolesti ili tjeskobe; depresije s ostatnim simptomima; kronične boli; poremećaja ili zlouporabe prehrane, pri čemu je navedena sol u tekućoj formulaciji.
The use according to claim 7, wherein said salt is the β form of the DL-lactic acid addition salt characterised by XRPD reflections at 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 and 13.58 (°2θ). 
Uporaba u skladu s patentnim zahtjevom 7, pri čemu je navedena sol β oblik dodatne soli DL-mliječne kiseline karakterizirana XRPD refleksijama na 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 i 13.58 (°2Ѳ).
The use according to claim 9, wherein said salt is the MH 2 form of the L-lactic acid addition salt characterised by XRPD at 5.33, 9.75, 10.10, 14.44 and 14.63 (°2θ). 
Uporaba u skladu s patentnim zahtjevom 9, pri čemu je navedena sol MH 2 oblik dodatne soli L-mliječne kiseline karakterizirana XRPD na 5.33, 9.75, 10.10, 14.44 i 14.63 (°2Ѳ).
A salt of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine selected from the DL-lactic acid addition salt, the L-lactic acid addition salt and the D-lactic acid addition salt for use in the treatment of a disease selected from mood disorders; major depressive disorder; general anxiety disorder; panic disorder; post traumatic stress disorder; depression associated with cognitive impairment, Alzheimer's disease or anxiety; depression with residual symptoms; chronic pain; eating disorder or abuse, wherein said salt is in a liquid pharmaceutical formulation. 
Sol 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina izabrane između dodatka soli DL-mliječne kiseline, dodatka soli L-mliječne kiseline i dodatka soli D-mliječne kiseline za liječenje bolesti odabrane između poremećaja raspoloženja; značajnog depresivnog poremećaja; općeg anksioznog poremećaja; paničnog poremećaja; posttraumatskog stresnog poremećaja; depresije povezane s kognitivnim nedostatkom, Alzheimerove bolesti ili tjeskobe; depresije s ostatnim simptomima; kronične boli; poremećaja ili zlouporabe prehrane, pri čemu je navedena sol u tekućoj farmaceutskoj formulaciji.
The compound according to claim 18 which is the MH 2 form of the L-lactic acid addition salt characterised by XRPD at 5.33, 9.75, 10.10, 14.44 and 14.63 (°2θ). 
Tvar u skladu s patentnim zahtjevom 18 koja je MH 2 oblik dodatne soli L-mliječne kiseline karakterizirana XRPD na 5.33, 9.75, 10.10, 14.44 i 14.63 (°2Ѳ).
A compound which is the β form of the DL-lactic acid addition salt characterised by XRDP reflections at 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 and 13.58 (°2θ). 
Tvar koja je β oblik dodatne soli DL-mliječne kiseline karakterizirana XRPD refleksijama na 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 i 13.58 (°2Ѳ).
A process according to any one of claims 1 to 5, characterized in that the inert reaction medium is selected from the group consisting of diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl-methylether, diisopropylether or any mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time da je inertni reakcijski medij u koraku (a) izabran iz skupine koja se sastoji od dietil etera, tetrahidrofurana, 2-metiltetrahidrofurana, terc-butil-metiletera, diizopropiletera ili bilo koje njihove smjese.
A process for the preparation of a compound of formula (V), said process comprising the step of: 
Postupak dobivanja spoja formule (V) [image], naznačen time što se navedeni postupak sastoji u koraku:
coupling a compound of formula (II) with compound of formula (IV) in a suitable solvent, in the presence of a coupling agent, and optionally in the presence of an activating agent of the coupling agent, or 
kondenziranja spoja formule (II) sa spojem formule (IV) [image], u pogodnom otapalu, u prisutnosti kondenzacijskog sredstva, te izborno u prisutnosti aktivacijskog sredstva za kondenzacijsko sredstvo; ili
A process for the preparation of a compound of formula (VII), a tautomer (VIIa), and salts thereof, as defined in claim 2, said process comprising the steps of: 
Postupak dobivanja spoja formule (VII), njegovog tautomera (VIIa), te njegovih soli, u skladu s patentnim zahtjevom 2, naznačen time što se navedeni postupak sastoji u koracima:
The process according to claim 4, where the reaction of a salt of compound of formula (IV) with a base is performed in the same reaction mixture of claims 1-3. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se reakciju soli spoja formule (IV) s bazom provodi u istoj reakcijskoj smjesi u skladu patentnim zahtjevima 1-3.